MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral synthesis or a chiral separation step in its preparation. Here, we report the SAR and medicinal chemistry design strategy, supported by structural insights from X-ray crystallography, to discover a class 1 atropisomeric compound from the same series that does not require a chiral synthesis or a chiral separation step in its preparation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2022.116947DOI Listing

Publication Analysis

Top Keywords

class atropisomeric
8
atropisomeric compound
8
chiral synthesis
8
synthesis chiral
8
chiral separation
8
separation step
8
step preparation
8
design evaluation
4
evaluation achiral
4
achiral non-atropisomeric
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!